Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00741429 · ClinicalTrials.gov registry record
A 2-Month Safety Follow-Up Trial
A clinical trial of Type 2 Diabetes and Type 1 Diabetes, sponsored by Mannkind Corporation.
- Completed
- Registry status
- 649
- Enrollment target
- 20
- Study locations
NCT00741429 is a study of Type 2 Diabetes and Type 1 Diabetes that has completed, run by Mannkind Corporation. The registered enrollment target is 649 participants, below the 1,100-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (41% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT00741429, a study of Type 2 Diabetes and Type 1 Diabetes, has completed, sponsored by Mannkind Corporation.
- COMPLETED
- Registry status
- 649 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of the trial is to evaluate pulmonary function in subjects who had completed any one of the 4 MKC parent trials (MKC-TI-009, MKC-TI-102, MKC-TI-103, or MKC-TI-030) for an additional 2-month safety follow-up.
Conditions Studied
Interventions
- DRUG Comparator
- DRUG Technosphere Insulin Inhalation Powder
Study Locations (20)
California
- Private Practice - Burlingame
- International Clinical Research Network - Chula Vista
- Family Medical Center - Foothill Ranch
- Saad Hijazi MD Inc - Fresno
- Saint Agnes Medical Center - Fresno
- Valley Research - Fresno
- Digestive & Liver Disease Specialist A Medical Group Inc - Garden Grove
- Diabetes/Lipid Management and Research Center - Huntington Beach
- Interlink Research Institute - Los Alamitos
- Southern California Endocrine Center - Pasadena
- Dorothy L & James E Frank Diabetes Research Institute - San Mateo
- Sansum Medical Research Institute - Santa Barbara
- Coastal Biomedical Research Inc - Santa Monica
Arizona
- Radiant Research (Phoenix) - Chandler
- Southwest Health Ltd Research Division - Phoenix
- Northwest Medical Center - Phoenix
- Canyon Clinical Research - Tucson
- Arizona Research Associates - Tuscon
Alabama
- Parkway Medical Center - Birmingham
- Coastal Clinical Research Inc - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 649 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00741429
The ClinicalTrials.gov registry entry for NCT00741429 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 649 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,100-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (41% lower). The listed sponsor is Mannkind Corporation, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Comparator is the first listed.
NCT00741429 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT00741429 about?
NCT00741429 is a clinical study titled "A 2-Month Safety Follow-Up Trial". The main purpose of the trial is to evaluate pulmonary function in subjects who had completed any one of the 4 MKC parent trials (MKC-TI-009, MKC-TI-102, MKC-TI-103, or MKC-TI-030) for an additional 2-month safety follow-up.
What is the current status of trial NCT00741429?
This trial is currently completed. The enrollment target is 649 participants. The study started on 2007-05. Estimated completion is 2008-09.
What conditions does trial NCT00741429 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Type 1 Diabetes.
What interventions are being tested in trial NCT00741429?
The interventions under investigation include: Comparator (DRUG), Technosphere Insulin Inhalation Powder (DRUG).
Who is sponsoring clinical trial NCT00741429?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00741429 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
Mechanism of SGLT2 Inhibition in the Kidney
RECRUITING · Phase 4
-
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.